OGEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ogen, and when can generic versions of Ogen launch?
Ogen is a drug marketed by Pharmacia And Upjohn and Pfizer and is included in two NDAs.
The generic ingredient in OGEN is estropipate. There are two drug master file entries for this compound. Additional details are available on the estropipate profile page.
US Patents and Regulatory Information for OGEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | OGEN | estropipate | CREAM;VAGINAL | 084710-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pfizer | OGEN 2.5 | estropipate | TABLET;ORAL | 083220-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pfizer | OGEN .625 | estropipate | TABLET;ORAL | 083220-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
